Australia markets open in 8 hours 31 minutes

Aligos Therapeutics, Inc. (5WK.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.6930-0.0210 (-2.94%)
At close: 06:19PM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 52.92M
Enterprise value -41.94M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.01
Price/book (mrq)0.98
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 2.34
52-week change 3-46.69%
S&P500 52-week change 326.27%
52-week high 31.3000
52-week low 30.5050
50-day moving average 30.8241
200-day moving average 30.7140

Share statistics

Avg vol (3-month) 3244
Avg vol (10-day) 3293
Shares outstanding 575.02M
Implied shares outstanding 676.36M
Float 837.78M
% held by insiders 120.39%
% held by institutions 160.53%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-942.67%

Management effectiveness

Return on assets (ttm)-36.63%
Return on equity (ttm)-89.48%

Income statement

Revenue (ttm)15.53M
Revenue per share (ttm)0.24
Quarterly revenue growth (yoy)-24.20%
Gross profit (ttm)N/A
EBITDA -85.84M
Net income avi to common (ttm)-87.68M
Diluted EPS (ttm)-1.2600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)135.7M
Total cash per share (mrq)1.79
Total debt (mrq)11.14M
Total debt/equity (mrq)12.10%
Current ratio (mrq)5.90
Book value per share (mrq)1.23

Cash flow statement

Operating cash flow (ttm)-79M
Levered free cash flow (ttm)-45.91M